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Michael S. Brown and Joseph L. Goldstein CoA reductase), which converts HMG CoA to the 6-car-
bon intermediate, mevalonate (Bucher et al. 1960; Sip-Department of Molecular Genetics
University of Texas erstein and Fagan, 1966). The latter is converted to iso-
pentenyl pyrophosphate, which is polymerized andSouthwestern Medical Center
Dallas, Texas 75235 modified to form the 27 carbons of cholesterol. Choles-
terol accumulation lowers the activity of HMG CoA re-
ductase and several other enzymes in the cholesterol
biosynthetic pathway, thereby limiting the productionAnimal cells must regulate their biosynthetic pathways
of cholesterol (reviewed in Goldstein and Brown, 1990).so as to produce the required amounts of end-products
The importance of the cholesterol feedback systemwithout risking overproduction. Such control is particu-
to human health was established by the finding thatlarly important in cholesterol homeostasis because cho-
diets rich in cholesterol and saturated fatty acids raiselesterol must be supplied for many cellular functions,
blood cholesterol levels and cause heart attacks (Keys,including two recently recognized ones: formation of
1975). In addition to suppressing synthesis of choles-caveolae (Smart et al., 1994; Murata et al., 1995) and
terol, high cholesterol diets act through the feedbackcovalent modification of embryonic signaling proteins
system to reduce the liver's uptake of cholesterol by(Porter et al., 1996). Excess cholesterol must be avoided
suppressing production of receptors for low densitybecause it forms solid crystals that kill cells. Excess
lipoproteins (LDL), thus causing these atherogenic par-cholesterol in the bloodstream is also lethal because it
ticles to accumulate in blood (Spadyet al., 1993; Goldsteindeposits in arteries, initiating atherosclerosis (Small and
et al., 1995). Conversely, the most potent cholesterol-Shipley, 1974). End-product regulation of cholesterol
lowering drugs, the HMG CoA reductase inhibitors,metabolism is achieved predominantly through repres-
exploit the feedback system by blocking cholesterolsion of transcription of genes that govern the synthesis
synthesis, thereby reducing the liver's content of choles-of cholesterol and its receptor-mediated uptake from
terol and increasing its production of LDL receptorsplasma lipoproteins (Goldstein and Brown, 1990).
(Brown and Goldstein, 1986; Goldstein et al., 1995).As an end-product repressor, cholesterol presents a
The SREBPs, which regulate transcription of HMGspecial problem because it is an insoluble lipid that
CoA reductase, also regulate transcription of genesresides almost exclusively in cell membranes. How does
encoding many other enzymes in the cholesterol biosyn-the cell sense the level of a membrane-embedded lipid,
thetic pathway, including HMG CoA synthase, farnesyland how is that information transmitted to the nucleus
diphosphate synthase, and squalene synthase (Goldsteinto regulate transcription? Answers are emerging from
and Brown, 1990; Osborne, 1995; Guan et al., 1995;studies of a novel family of membrane-bound transcrip-
Ericsson et al., 1996b). The SREBPs also regulate thetion factors called sterol regulatory element binding pro-
LDL receptor, which supplies cholesterol through recep-teins (SREBPs) that regulate multiple genes involved in
tor-mediated endocytosis. In a surprising turn of events,cholesterol biosynthesis and uptake. Here we review
the SREBPs, were found to modulate transcription ofthe SREBPs, focusing on the novel way in which sterols
genes encoding enzymes of fatty acid synthesis andregulate their proteolytic release from membranes. Re-
uptake, including acetyl CoA carboxylase, fatty acidmarkably, insight into this processing may teach us
synthase, stearoyl CoA desaturase-1, and lipoproteinabout Alzheimer's disease, themost common degenera-
lipase (Tontonoz et al., 1993; Kim and Spiegelman, 1996;tive disease of the brain, as well as coronary artery
Lopez et al., 1996; Magana and Osborne, 1996; Shimanodisease, the most common degenerative disease of the
et al., 1996). Thus, SREBPs coordinate the synthesis ofheart. Other aspects of SREBP physiology, such as the
the two major building blocksof membranes, fatty acids,DNA binding activities and interactions with other tran-
and cholesterol.scription factors, have been discussed elsewhere (Kim
et al., 1995; Osborne, 1995; Ericsson et al., 1996a; Ma-
gana and Osborne, 1996; Oliner et al., 1996). SREBPs: Membrane-Bound Transcription Factors
The SREBPs were purified in 1993 from nuclear extractsFrom a historical perspective, the cholesterol biosyn-
thetic pathway was the first anabolic pathway recog- of cultured human HeLa cells (Briggs et al., 1993; Wang
et al., 1993), and their unique mechanism of regulationnized to undergo end-product feedback suppression.
More than 60 years ago, the balance studies of Schoen- was also worked out in tissue culture (Wang et al., 1994).
Three members of the SREBP family have been identi-heimer and Breusch (1933) demonstrated that mice syn-
thesize less cholesterol after they have ingested it in fied by cDNA cloning (Yokoyama et al., 1993; Hua et al.,
1993). Each SREBP shares a similar tripartite structure,the diet. In the early 1950s, Gould et al. (1953) incubated
liver slices from dogs and rabbits with [14C]acetate and consisting of: (1) an NH2-terminal transcription factor
domain of z480 amino acids; (2) a middle hydrophobicobserved that its incorporation into cholesterol was
reduced to less than 2% of the control value when region of z80 amino acids containing two hydrophobic
transmembrane segments; and 3) a COOH-terminal reg-cholesterol had been supplied in the diet. In the 1960s
an important enzymatic site for this regulation was ulatory domain of z590 amino acids (Figure 1).
In humans, hamsters, and mice, two members of theidentified as the endoplasmic reticulum (ER) enzyme
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG SREBP family, designated SREBP-1a and SREBP-1c,
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between the SREBP-1s and SREBP-2. These sequences
are followed by a classic bHLH-Zip sequence that re-
sembles the sequence first identified in E12/E47, which
binds to the immunoglobulin enhancer. Similar se-
quences are found in MyoD, Myc, and Max proteins,
and in more than a score of other DNA binding proteins,
all of which regulate transcription (Murre and Baltimore,
1992).
The basic regions of bHLH-Zip proteins bind to spe-
cific sequences in DNA, and the adjacent HLH-Zip
regions mediate homo- or heterodimerization. All bHLH-
Figure 1. Domain Structures of Human SREBP-1a and SREBP-2
Zip proteins other than SREBPs bind to target se-
The sequence of SREBP-1c (not shown) is identical to that of
quences called E boxes, which are inverted repeats ofSREBP-1a except for a shortened NH2-terminal acidic domain (24
the sequence CANNTG (Murre and Baltimore, 1992).amino acids in SREBP-1c versus 42 amino acids in SREBP-1a).
Although SREBPs can recognize E boxes in vitro, in the
nucleus they bind to sequences that contain a direct
are produced from a single gene (human chromosomal repeat of 59-PyCAPy-39 (Magana and Osborne, 1996).
location, 17p11.2) through the use of alternate transcrip- In the LDL receptor the recognition site is 59-ATCACCC
tion start sites encoding alternate first exons that are CAC-39, which is designated sterol regulatory element 1
spliced into a common second exon (Yokoyama et al., (SRE-1) (Yokoyama et al., 1993). Kim et al. (1995) showed
1993; Hua et al., 1995b; Shimomura et al., 1997). The that the ability of SREBPs to recognize a direct, rather
ADD1 transcription factor cloned from a rat adipocyte than inverted, repeat depends on a tyrosine that re-
cDNA library by Tontonoz et al. (1993) is equivalent to places an arginine found in all other bHLH-Zip proteins.
SREBP-1c (Shimomura et al., 1997). The mRNAs for In their elegant studies of the crystal structure of the
human SREBP-1a and -1c can also undergo alternative DNA binding and dimerization domains of SREBP-1a
splicing at the 39 ends to produce proteins that differ in bound to SRE-1, Burley and coworkers (Parraga et al.,
the last 113 amino acids (Yokoyama et al., 1993; Hua et unpublished data) explained the effects of the tyrosine
al., 1995b). This 39 alternative splicing does not occur substitution by showing that it enhances the mobility of
in the mouse (Hua et al., 1995b; Shimomura et al., 1997), the DNA binding domain, removing the requirement for
and its functional significance is not apparent. an inverted repeat.
The third member of the SREBP family, designated The SREBPs are distinguished from other members
SREBP-2, is encoded by a separate gene on human of the bHLH-Zip family by virtue of the unique sequence
chromosome 22q13 (Hua et al., 1993; Miserez et al., that follows the bHLH-Zip region, which consists of the
1997). Thus far, only one transcript from this gene has following: (1) a hydrophobic membrane-spanning se-
been demonstrated in humans, hamsters, and mice. De- quence of z22 amino acids, (2) a hydrophilic ``lumenal
spite the differences in lengths of the human SREBP-1 loop'' of z31 amino acids, (3) a second hydrophobic
and -2 genes (26 kb versus 72 kb), the locations of membrane-spanning sequence of z22 amino acids, and
the exon±intron boundaries in both genes are similar (4) a long COOH-terminal extension of z590 amino acids
(Miserez et al., 1997). A Drosophila homolog of the that is necessary for sterol-regulated cleavage (Figure
SREBPs has recently been cloned (Theopold et al., 1). Immunofluorescence, protease protection, and gly-
1996). Its overall tripartite domain structure, including cosylation site tagging experiments indicate that the
the two transmembrane segments, is virtually identical SREBPs are bound to membranes of the ER and nuclear
to that of the mammalian SREBPs. envelope in a hairpin fashion with the large NH2-terminal
The NH2-terminal domain of z480 amino acids of each and COOH-terminal segments facing the cytoplasm and
SREBP is a transcription factor of the basic-helix-loop- the short 31-residue lumenal loop projecting into the
helix-leucine zipper (bHLH-Zip) family. This segment be- lumen of the organelle (Hua et al., 1995a; Duncan et al.,
gins with an acidic domain that resembles the ``acid 1997).
blobs'' of many transcriptional activators (Figure 1).
When this segment is deleted in transfection studies, A Proteolytic Cascade
the proteins retain the ability to bind to the relevant In order to influence transcription, the NH2-terminal do-
DNA sequence, but they lose their ability to activate main of SREBPs must be released from the membrane
transcription, so they are converted to inhibitors of tran- so that it can enter the nucleus. This release has been
scription (Sato et al., 1994). The acidic NH2-terminal do- studied most extensively for SREBP-2. Release is ac-
main in human SREBP-1a comprises 42 amino acids, complished by a two-step proteolytic cascade that is
of which 12 are acidic. In human SREBP-2, this domain regulated by sterols (Wang et al., 1994; Hua et al., 1996b;
contains 48 amino acids (14 acidic), but in SREBP-1c it Sakai et al., 1996). In sterol-depleted cells the cascade
contains only 24 amino acids (6 acidic). The shortened is initiated by a protease that clips SREBP-2 at site
acidic domain in SREBP-1c, which results from use of 1, which is located approximately in the middle of the
a first exon containing a shorter coding region, renders lumenal loop (Figure 2, upper panel). The site 1 protease
SREBP-1c a much weaker activator of transcription than cleaves between the leucine and serine in the sequence
is SREBP-1a (Shimano et al., 1997) or SREBP-2. The RSVL S (Duncan et al., 1997). Cleavage is absolutely
acidic NH2-terminal sequence is followed by sequences dependent on a positively charged residue, either argi-
nine or lysine, at the P4 position. The serine and valinerich in proline, serine, glycine, and glutamine that vary
Review
333
Figure 3. Immunofluorescence of SREBP-2 in Cultured Fibroblasts
Grown in Whole Serum or Lipoprotein-Deficient Serum
Monolayers of diploid human fibroblasts were cultured for 4 days
in 10% fetal calf serum. On day 5, the cells were either re-fed with
10% fetal calf serum (left panel) or switched to 10% lipoprotein-
deficient serum (right panel). On day 6, the cells were fixed with
paraformaldehyde and stained with a rabbit anti-SREBP-2 poly-
clonal antibody (affinity purified), followed by fluorescein-labeled
goat anti-rabbit IgG. Magnification, 4503.
Cleavage at site 1 is tightly regulated by sterols (Wang
et al., 1994; Sakai et al., 1996). When cultured cells such
as CHO cells, HeLa, or human embryonic kidney 293
cells are deprived of sterols, cleavage at site 1 is active.
Figure 2. Model for Two-Site Proteolytic Cleavage of Membrane-
This cleavage is abolished when cells are overloadedBound SREBPs
with sterols by incubation with LDL or a mixture of cho-
Abbreviations: bHLH, basic-helix-loop-helix-leucine zipper domain
lesterol and 25-hydroxycholesterol. Cleavage at site 2of SREBP; Reg., regulatory domain of SREBP.
is not directly regulated by sterols, but it requires prior
cleavage at site 1. Hence, it occurs only in sterol-
depleted cells.at the P3 and P2 positions can be replaced with alanines
without loss of cleavage. Leucine is strongly preferred The sterol-regulated proteolysis of SREBPs is illus-
trated visually in Figure 3, which shows cultured humanat the P1 position. Substitutions with valine, alanine,
phenylalanine, arginine, or glutamic acid either abolish fibroblasts that were stained for endogenous SREBP-2
with an antibody directed against the NH2 terminus. Inor markedly reduce cleavage activity. The serine at the
P91 position can be replaced with a variety of amino fibroblasts grown in whole serum, which supplies LDL-
cholesterol, SREBP-2 was located in extranuclear mem-acids without affecting cleavage. Although single ala-
nine substitutions at other positions in the lumenal loop branes (left panel). When the cells were deprived of
cholesterol by growth in lipoprotein-deficient serum, thedo not reduce cleavage, it is believed that structural
features of the surrounding sequences are required NH2-terminal fragment of SREBP-2 was released from
the membranes and entered the nucleus (right panel).since movement of the RSVL tetrapeptide to other posi-
tions in the lumenal loop markedly decreases cleavage SREBP-1 behaves similarly in these cells.
The crucial role of the proteolytic cascade in sterol(Duncan et al., 1997).
Cleavage at site 1 breaks the covalent bond between regulation is revealed by transfection experiments with
cDNAs encoding truncated versions of the SREBPs thatthe two transmembrane domains of SREBP-2, but both
halves of the protein remain attached to membranes terminate before the first transmembrane domain (Sato
et al., 1994; Yang et al., 1994, 1995). These proteins(Figure 2, middle panel). Shortly thereafter, a second
protease clips the NH2-terminal fragment at site 2, which contain the bHLH-Zip domain and all of the other se-
quences necessary for transcriptional activation; how-appears to reside within the first transmembrane domain
(Sakai et al., 1996). This releases the mature NH2-termi- ever, they are never attached to membranes, and they
enter the nucleus directly without a requirement for pro-nal domain into the cytosol, from which it rapidly enters
the nucleus, apparently with a portion of the transmem- teolysis. In cells expressing these truncated proteins,
the SREBP-dependent genes are continuously acti-brane domain still attached at the COOH terminus (Fig-
ure 2, lower panel). Cleavage at site 2 is strongly depen- vated, and they cannot be suppressed by sterols. When
these cells are grown in the presence of serum thatdent on the tetrapeptide DRSR that precedes the first
transmembrane domain (Hua et al., 1996b; Sakai et al., contains LDL, they fill up with huge amounts of choles-
teryl esters,owing to continuousnonregulated synthesis1996). Substitutions in this tetrapeptide abolish cleav-
age at site 2, and the NH2-terminal fragment remains in of cholesterol and uptake of LDL.
Thus far there is no in vitro biochemical descriptiona membrane-bound state.
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of the proteases that cleave at site 1 or site 2. Both are loops (Hua et al., 1996a). The hydrophilic COOH-terminal
domain of SCAP comprises 546 amino acids organizedpredicted to be unusual enzymes. The site 1 protease
is unusual in that it appears to function in the lumen of into four repeats of a sequence belonging to a family
designated WD, which are reiterated in many proteinsthe ER, and it recognizes a tetrapeptide sequence,
RSVL, which is unlike any known protease substrate. (Neer et al., 1994). The best understood is the b subunit
of heterotrimeric G proteins, which contains seven WDThe site 2 protease is unusual because it appears to
cut SREBP within a membrane-spanning segment as repeats that are arrayed in a fan shape like the blades
of a propeller (Wall et al., 1995; Sondek et al., 1996).estimated from a careful analysis of the size of the liber-
ated fragments (Sakai et al., 1996). The location of site Variable sequenceson the surface of each blade interact
with other proteins. WD repeats have been found in2 in the transmembrane sequence is consistent with
sequence analysis of tryptic peptides prepared from more than 30 proteins, and in each case they have been
postulated to mediate protein±protein interactions (NeerSREBP-1 that was purified fromnuclear extracts of HeLa
cells (Yokoyama et al., 1993). One of the tryptic peptides et al., 1994).
The most intriguing aspect of SCAP is the sequence(peptide 1) terminated at an arginine that is 4 residues
to the NH2-terminal site of the DRSR sequence. This resemblance of its hydrophobic NH2-terminal domain to
the corresponding domain of HMG CoA reductase (Huaconfirms that the nuclear NH2-terminal fragment of
SREBP-1 extends at least to the first transmembrane et al., 1996a). Like SCAP, HMG CoA reductase has an
NH2-terminal membrane-attachment domain with eightdomain.
The cellular locations of the two proteases are not membrane-spanning segments (Olender and Simoni,
1992). It also has a cytoplasmic COOH-terminal domainknown. Immunofluorescence studies show that the
full-length SREBP precursors are located in the ER and that contains all of the catalytic activity (Liscum et al.,
1985). The NH2-terminal domain imparts sterol regula-nuclear envelope (Sato et al., 1994). Moreover, when
N-linked glycosylation sites were inserted into the lume- tion. In sterol-depleted cells the enzyme has a long half-
life, but it is degraded rapidly when sterols accumulate.nal loop, the carbohydrate chains on the precursor re-
mained in the highmannose endoglycosidase H±sensitive Regulated degradation depends on the membrane at-
tachment domain, and it is abolished when this domainform, indicating that the precursor had not been trans-
ported to the Golgi complex (Hua et al., 1995a; Duncan isdeleted (Gil et al., 1985). Studies with chimeric proteins
have also implicated the membrane-spanning domainet al., 1997). We therefore believe that thesite 1 protease
acts in the lumen of the ER and the contiguous nuclear in the sterol-sensing function (Kumagai et al., 1995). The
NH2-terminal domain of SCAP (amino acids 280±444)envelope. However, we cannot exclude the possibility
that prior to cleavage the precursor is transported to shows 25% identity and 55% similarity to the region of
HMG CoA reductase that corresponds to membrane-the Golgi complex where cleavage immediately occurs.
The site 2 protease may also function in the ER, but it spanning segments 2±6, implying that this domain in
SCAP, like its counterpart in HMG CoA reductase, hasseems equally likely that this enzyme is located in a
more distal site such as the Golgi complex. By one a sterol-sensing function (Hua et al., 1996a).
The mutant SCAP produced in 25-RA cells has anhypothetical scenario, cleavage at site 1 in the ER sepa-
rates the two halves of the protein, allowing the NH2- asparagine substituted for aspartic acid at residue 433,
which is just at the cytoplasmic side of the last of theterminal intermediate to move to the Golgi where it en-
counters the site 2 protease. membrane-spanning segment that resembles HMG CoA
reductase (Hua et al., 1996a). When expressed at low
levels that approximate physiologic concentrations, the
SREBP Cleavage Activation Protein, SCAP mutant SCAP stimulates cleavage of SREBPs at site
Recently an important regulator of SREBP processing, 1, and it renders the cleavage reaction insensitive to
designated SCAP, was cloned from 25-RA cells, a mu- inhibition by sterols. Wild-type SCAP can have a similar
tant line of CHO cells that fails to suppress cleavage of effect, but only when expressed at 10-fold higher levels.
SREBPs in the presence of sterols (Hua et al., 1996a). The mutant 25-RA cells have one copy of the mutant
These cells continue to synthesize cholesterol and to SCAP and one copy of the wild-type gene, and yet they
take up LDL even when they are massively overloaded exhibit a sterol-resistant phenotype, attesting to thegain
with sterols. Cell fusion studies by Hasan and Chang of potency imparted by the D443N mutation (Hua et al.,
(1994) showed that the defect was semidominant, pre- 1996a). Remarkably, the same nucleotide substitution
sumably representing a gain of function. Transient trans- (G→A in codon 443) recurred in two other CHO cell lines
fection of a cDNA library from 25-RA cells into 293 cells that were mutagenized and selected for sterol resis-
allowed our laboratory to isolate a cDNA that encodes tance. Although the mutagens used favor G→A transi-
a mutantversion of a novelprotein named SCAP (SREBP tions, the involvement of the same G in all three of these
cleavage activating protein.) (Hua et al., 1996a). The cell lines attests to the specificity of the D443N substitu-
mutant SCAP stimulates cleavage of SREBPs, even in tion in rendering SCAP sterol resistant (Nohturfft et al.,
the presence of sterols, thus explaining the sterol-resis- 1996).
tant phenotype of 25-RA cells. We interpret these data to indicate that SCAP is a
SCAP is a membrane-bound protein with two do- required activator of SREBP cleavage and that the activ-
mains. The NH2-terminal 730 amino acids consist of ity of the wild-type protein is abolished by sterols.
alternating hydrophobic and hydrophilic sequences. Mutant SCAP is both superactive and sterol resistant.
These are predicted to form up to eight membrane- SCAP may act by binding SREBPs, perhaps through an
interaction of the cytoplasmic WD repeat region ofspanning sequences separated by short hydrophilic
Review
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Table 1. Mutant Hamster Cells with Defects in SREBP Processing
Phenotype Molecular Defect Mutant Cell Lines
Sterol-Resistanta
Class 1 Truncated SREBP-2 at amino acid 460 SRD-1, SRD-2, SRD-3
Class 2 Activating mutation in SCAP, Asp 443→Asn 25-RA, SRD-4, SRD-8
Sterol-Requiringb Failure to cleave SREBP-1 and SREBP-2 at Site 2 M19, SRD-6
a Unable to repress synthesis of cholesterol and LDL receptors in response to sterol excess.
b Unable to induce synthesis of cholesterol and LDL receptors in response to sterol depletion.
SCAP and the cytoplasmic COOH-terminal domain of that each recombination involves the intron following
codon 460, and not the intron following codon 400,SREBP. Although there are no published data to support
this model, it is attractive for two reasons: (1) the which should have produced a similar phenotype (Yang
et al., 1995). The recurrent involvement of the sameCOOH-terminal regulatory domain of SREBPs is re-
quired for site 1 cleavage (Hua et al., 1996b); and (2) intron is not attributable to a recombination ``hot spot''
since different sites of recombination are found in eachWD repeats, in general, mediate protein±protein interac-
tions. If SREBP±SCAP binding does occur, the complex of the mutants. This recurrence more likely results from
the size of the intron in SREBP-2 (z3100 bp), which ismight serve as the site of attachment of the lumenal
protease that cuts SREBPs at site 1. SCAP itself has no larger than the other introns at which recombination
could produce the same phenotype (Yang et al., 1995).hallmarks of a protease, and to date none of the proteins
that contain WD repeats has been shown to be an en- Apparently, the large intron in SREBP-2 increases the
probability that a recombination event will occur. Whenzyme. If SCAP±SREBP binding is necessary for site 1
proteolysis, it is possible that sterols disrupt proteolysis this creates a desirable phenotype, such as escape from
sterol-mediated down-regulation, the cells gain the abil-by blocking this binding. The simplest mechanismwould
invoke a sterol-mediated increase in the degradation of ity to survive under the selective conditions employed.
This finding illustrates the advantage of introns inprovid-SCAP, much as sterols accelerate the degradation of
HMG CoA reductase. So far, however, we have been ing the genomic diversity that allows rapid evolution by
recombination and selection.unable to obtain evidence that sterols acutely decrease
the amount of immunodetectable SCAPin cultured cells. The other type of CHO cell mutant, the cholesterol
auxotroph, has also taught us much about SREBP pro-
cessing (Table 1). The original cell line with this pheno-Mutant Cells with Defects in Processing of SREBPs
Two types of regulatory mutants in sterol metabolism type, M19 cells, was isolated by Chin and Chang (1981).
The cells were shown to have three phenotypic abnor-have been isolated in appropriate selective media: (1)
sterol-resistant cells, like the 25-RA cells described malities: (1) failure to induce cholesterol biosynthetic
enzymes such as HMG CoA synthase and HMG CoAabove, that fail to suppress enzymes of cholesterol syn-
thesis or LDL receptors in response to cholesterol or reductase upon sterol deprivation, thus explaining the
cholesterol auxotrophy; (2) failure to induce the LDLoxygenated sterols such as 25-hydroxycholesterol; and
(2) cholesterol auxotrophs, which fail to induce the en- receptor, indicating that the cells have a global failure to
induce sterol-repressed genes upon sterol deprivation;zymes of cholesterol synthesis or LDL receptors upon
sterol deprivation (reviewed in Chang et al., 1997). Both and (3) a requirement for unsaturated fatty acids, in
addition to cholesterol, for cell growth. As discussedof these phenotypes result from defects in regulation of
SREBP cleavage. Table 1 reviews the mutant hamster below, all of these defects can now be traced to a single
abnormality: failure of the site 2 protease to release thecell lines in which the molecular defect has been charac-
terized. NH2-terminal fragment of SREBPs from cell membranes.
In recent studies, Sakai et al. (1996) showed that twoThe sterol-resistant mutants are divided into two
classes. Class 2 includes the 25-RA cells and other CHO independently derived cholesterol auxotrophic CHO cell
lines, the M19 cells of Chin and Chang (1981) and thecell lines that produce a dominantly acting mutant
SCAP. Class 1 mutants are sterol resistant because they SRD-6 cells from our laboratory (Evans and Metherall,
1993), exhibited normal cleavage of SREBPs at site 1produce a nonsuppressible form of SREBP-2 that is
truncated at residue 460, which is between the bHLH- following sterol deprivation. However, cleavage at site
2 did not follow, and the NH2-terminal fragments ofZip domain and the first transmembrane segment. Three
mutant cell lines of this class have been isolated, and SREBPs accumulated in the membrane-bound interme-
diate form. Hasan et al. (1994) showed that the defectall have undergone recombinations in the intron follow-
ing the exon that terminates at codon 460 of SREBP-2 in M19 cells is recessive and that it can be corrected
by transfection of DNA from a human genomic library.(Yang et al., 1994, 1995). The resulting mRNAs encode
fusion proteins whose SREBP-2 sequence terminates This finding should permit the cloning of the gene that
is defective in the M19 cells. This gene may encodeat codon 460. Since these proteins are never attached
to membranes, they proceed to the nucleus directly the site 2 protease or another protein whose action is
required for cleavage by this enzyme.without requiring proteolysis. Thus, they are immune
from sterol down-regulation, and they confer a sterol- The defect in site 2 proteolysis and the consequent
failure of SREBPs to enter the nucleus explain the failureresistant phenotype. It is interesting that each of the
three mutants involves SREBP-2, and not SREBP-1, and to produce cholesterol and LDL receptors. But do they
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explain the requirement for unsaturated fatty acids? An primarily on the liver because of its importance in whole-
body homeostasis of cholesterol and fatty acids. Theanswer to this question was suggested recently by stud-
ies in transgenic mice which indicate that SREBPs may results have highlighted important contrasts between
liver and cultured cells.be required to activate transcription of the gene encod-
ing stearoyl CoA desaturase 1, an enzyme that synthe- In a large variety of cultured cells, including the HepG2
line of human hepatocytes and the 3T3-L1 line of mousesizes unsaturated fatty acids (see below).
preadipocytes, expression of SREBP-1a, with its long
acidic activation domain, exceeds that of SREBP-1c
SREBPs and Fatty Acid Synthesis by more than a 2:1 ratio (Shimomura et al., 1997).
SREBPs were first implicated in regulating fatty acid SREBP-2 is also produced at high levels in these cells.
synthesis by Tontonoz et al. (1993), who isolated a cDNA The proteolytic processing of SREBP-1a and SREBP-2
encoding rat ADD1 in a screen for adipose tissue cDNAs is regulated in parallel. They are both cleaved at site 1
that encode bHLH proteins that bind to E boxes. ADD1 (and therefore at site 2) when cells are deprived of ste-
is the rat homolog of human and mouse SREBP-1c (Shi- rols, and their cleavage is suppressed by sterols.
momura et al., 1997). Tontonoz et al. (1993) showed that A different situation exists in livers of hamsters. When
overexpression of ADD1/SREBP-1c stimulated tran- hamsters were fed a typical low-fat chow diet, their
scription of a reporter gene driven by a polymerized liver nuclei contained the mature form of SREBP-1, but
set of E boxes derived from the fatty acid synthase relatively little SREBP-2 (Sheng et al., 1995). When the
promoter. Magana and Osborne (1996) then showed liver was depleted of cholesterol by feeding a diet con-
directly that the NH2-terminal domain of SREBP-1a and taining the cholesterol synthesis inhibitor lovastatin and
SREBP-2 activates the authentic fatty acid synthase the bile acid±binding resin Colestipol, the total amount
promoter. Surprisingly, this effect was mediated not by of SREBP-2 increased, and the efficiency of its proteo-
the E box, but by an adjacent sequence that contains lytic processing rose markedly, as expected. Paradoxi-
two SRE-1-like sequences that flank the E box. Lopez cally, the processing of SREBP-1 became less efficient.
et al. (1996) showed that SREBP-1a stimulates transcrip- As a result, sterol-depleted liver nuclei contained much
tion of the gene encoding acetylCoA carboxylase, which more mature SREBP-2 than SREBP-1 (Sheng et al.,
provides the malonyl CoA substrate for fatty acid syn- 1995). This rise in SREBP-2 was accompanied by a
thase. When transfected into cultured 3T3-L1 preadipo- marked increase in the amounts of target mRNAs for
cytes, ADD1/SREBP-1c enhances the program of adipo- cholesterol-related genes, including HMG CoA reduc-
cyte differentiation by stimulating expression of genes tase, HMG CoA synthase, and the LDL receptor. A rea-
for fatty acid biosynthesis (Kim and Spiegelman, 1996). son for the reciprocal regulation of SREBP-1 and -2 in
The implication of SREBPs in regulating fatty acid liver was suggested when the relative distribution of
synthesis was surprising since nuclear SREBPs are sup- SREBP-1a and -1c were studied in this organ (Shimo-
pressed by cholesterol and since cholesterol overaccu- mura et al., 1997). In livers of mice and humans, the
mulation was not known to suppress fatty acid biosyn- SREBP-1c transcript exceeded the -1a transcript by
thesis. In the classic experiments of Gould et al. (1953) 9-fold, which is directly opposite to the ratio in cultured
and Siperstein and Fagan (1966), the feeding of choles- cells. If this distribution in hamster liver is similar to that
terol to animals shut down cholesterol synthesis in the in liver of mice and humans, then in liver cholesterol de-
liver, but it had only small effects on fatty acid synthesis. pletion specifically inhibits the processing of SREBP-1c
Similarly, in the early experiments of Goldstein et al. at the same time that it activates the processing of
(1974) in human fibroblasts, cholesterol overloading SREBP-2.
nearly abolished cholesterol synthesis from acetate, but The potential significance of these tissue-specific dif-
it did not substantially reduce fatty acid biosynthesis. ferences became apparent when the transcriptional ac-
The lack of an absolute requirement for SREBPs in fatty tivities of SREBP-1c and SREBP-1a were compared
acid biosynthesis is supported by observations in the quantitatively by transfection into cultured cells. When
mutant M19 line of CHO cells described above. These expressed at levels that are many-fold above thephysio-
cells fail to process SREBPs normally and they therefore logic range, the mature NH2-terminal fragments of
require exogenous cholesterol for growth. The rate of SREBP-1a and -1c were both able to stimulate transcrip-
cholesterol synthesis in these cells is ,5% of normal, tion of reporter genes driven by the promoters for the
indicating that this process absolutely requires SREBPs, LDL receptor, HMG CoA synthase, and fatty acid syn-
whereas the rate of fatty acid synthesis is z30% of thase (Shimano et al., 1997). However, at lower levels
normal (Pai et al., unpublished data). of expression that approximated the physiologic range,
These observations can be reconciled by the sugges- SREBP-1a was 10-fold more potent than SREBP-1c with
tion that SREBPs act as auxiliary regulators of the fatty respect to the LDL receptor and HMG CoA synthase
acid biosynthetic enzymes by elevating their transcrip- promoters, but only about 2-foldmore potent instimulat-
tion above a basal level under certain circumstances. ing fatty acid synthase (Shimano et al., 1997).
Under other circumstances, alternative factors can re- The liver is not the only organ that produces an abun-
place the SREBPs. dance of SREBP-1c relative to -1a. A similar situation
exists in mouse adipose tissue where the level of
SREBP-1c mRNA exceeds that of SREBP-1a by 3-fold
SREBPs in Liver (Shimomura et al., 1997). Here the contrast between in
All of the early studies of SREBPs were performed in vivo and in vitro is particularly striking since cultured
cultured cells, and the results have only recently been preadipocytes (mouse 3T3-L1 cells) produce SREBP-
1aalmost exclusively, even after they have been inducedextended to in vivo metabolism. These studies focused
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Figure 4. Livers from 18-Week-Old Litter-
mate Wild-Type and Transgenic Mice
The transgene encodes a truncated version
of SREBP-1a (amino acids 1±460) driven by
the phosphoenolpyruvate carboxykinase pro-
moter. Both animals (wild type, left; trans-
genic, right) were fed a low carbohydrate/
high protein diet for 2 weeks to induce ex-
pression of the transgene.
to differentiate into adipocytes in tissue culture (Shimo- nuclei triggereda program of lipid synthesis and seques-
tration, rather than one of lipid secretion. Despite themura et al., 1997). This differentiation is known to be
massive increase in stores of triglycerides and choles-accompanied by a marked increase in SREBP-1 mRNA
teryl esters, there was no increase in the mRNAs for(Kim and Spiegelman, 1996), but the mRNA that in-
apolipoproteins required for lipoprotein assembly andcreases is SREBP-1a, not SREBP-1c (also known as
secretion (such as apo B, apo E, and apo A-I) (ShimanoADD1).
et al., 1996). Plasma triglyceride levels were actuallyAs mentioned above, SREBP-1c retains some ability
lower in the transgenics than in wild-type littermates fedto stimulate fatty acid synthesis, but it has very little
the same diet (Shimano et al., 1997). There was also aability to stimulate cholesterol synthesis (Shimano et al.,
progressive decrease in the mass of white adipose tis-1997). These results have led to a working model that
sue throughout the body. It is not known whether thepostulates that liver and other adult organs produce
latter is attributable to the high-level expression of theSREBP-1c in the basal state to support fattyacid synthe-
SREBP-1a NH2-terminal fragment in adipose tissue nu-sis, albeit at a low level. When demands for cholesterol
clei, or whether it is a consequence of fat accumulationincrease, the liver produces more SREBP-2 and pro-
in the liver, which might deprive adipose tissue of fattycesses it more efficiently, thereby activating cholester-
acids through a ``triglyceride steal'' syndrome (Shimanool synthesis. Tissue culture cells, on the other hand,
et al., 1996).need cholesterol constantly for membrane synthesis
In contrast to the truncated SREBP-1a, which hadduring growth, and they produce SREBP-1a as well as
profound effects on hepatic lipid metabolism, overex-SREBP-2, which gives them a higher potential for cho-
pression of the corresponding version of SREBP-1c hadlesterol synthesis.
a much less pronounced effect in transgenic mice (Shi-The dramaticconsequences of overproducing a domi-
mano et al., 1997). The livers were mildly enlargednant positive form of SREBP-1a in mouse liver are shown
(z33% above normal), and there was a slight increasein Figure 4. In these experiments, Shimano et al. (1996)
in cholesterol content and a more pronounced 4-foldproduced transgenic mice that overexpress an NH2-ter- increase in triglycerides. The levels of the mRNAs for
minal fragment of human SREBP-1a that terminates at
the LDL receptor and cholesterol biosynthetic enzymes
residue 460, which is between the bHLH-Zip domain
were not elevated, and the mRNAs for acetyl CoA car-
and the first transmembrane domain. Expression was
boxylase and fatty acid synthase were increased by only
driven by the phosphoenolpyruvate carboxykinase pro-
2- to 4-fold as compared with 20-fold in the transgenics
moter, which gives high level expression in the liver and
expressing comparable amounts of truncated SREBP-
other organs when the animals are placed on a low 1a. These results reflect the relatively weak ability of
carbohydrate/high protein diet. The livers of these ani- SREBP-1c to stimulate transcription, as discussed
mals were massively enlarged (up to 4-fold above nor- above. They also point out that SREBP-1c seems to
mal), owing to massive engorgement with triglycerides exert a greater effect on the fatty acid biosynthetic
and cholesteryl esters. Despite this engorgement,which pathway as opposed to the cholesterol biosynthetic
should have triggered feedback repression, the livers pathway.
continued to synthesize cholesterol and fatty acids at Thus far, there are no published studies of transgenic
rates that were 5-fold and 20-fold greater than normal, mice expressing the NH2-terminal domain of SREBP-2.
respectively. The mRNAs for the cholesterol biosyn- Inasmuch as this protein is normally up-regulated in
thetic enzymes HMG CoA synthase, HMG CoA reduc- response to demands for cholesterol (Sheng et al.,
tase, and squalene synthase were elevated from 5- to 1995), it seems likely that the SREBP-2 transgenics
37-fold. The mRNAs for the fatty acid±synthesizing en- should show a relatively selective increase in cholesterol
zymes, acetyl CoA carboxylase and fatty acid synthase, biosynthesis. Experiments to test this hypothesis are
were elevated 17- to 20-fold, and the mRNA encoding under way.
stearoyl CoA desaturase 1 was increased by 4-fold.
There was also a 6-fold increase in themRNA for the LDL Parallels between Processing of SREBPs
receptor and a 25-fold increase in the mRNA encoding and b-Amyloid Precursor Protein
lipoprotein lipase. b-Amyloid precursor protein (bAPP) is a 770±amino acid
cell surface protein with a single membrane-spanningThe nonregulated expression of SREBP-1a in liver
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